

**BUY**

TP: Rs 523 | ▲ 19%

ITC

Consumer Staples

20 October 2023

## FMCG and hotels continue to shine

- **FMCG business delivered strong topline (+8% YoY) growth in Q2 led by steady portfolio expansion**
- **Hotels segment grew 21% YoY on the back of strong growth in ARR; EBIT swelled 50% led by retail and MICE**
- **Expect deepening rural recovery to aid growth; maintain BUY with an unchanged SOTP-based TP of Rs 523**

**Vikrant Kashyap**

research@bobcaps.in

**FMCG and hotels lead growth:** ITC posted 3.9% YoY revenue growth to Rs 177.7bn in Q2FY24 despite (i) a slowdown in agricultural business on account of the ban on wheat exports, and (ii) a subdued performance in the paper and paperboard segment owing to poor demand in domestic and global markets and cheap Chinese supply. The cigarettes business continued to perform well, growing 9.1% YoY for the quarter, FMCG-others revenue was up 8.3%, and the hotels segment climbed 21.2% YoY (1.5x Q2FY20) despite a high base.

**Margin expands despite stress in paper business:** ITC's EBITDA margin increased 230bps YoY (-260bps QoQ) to 36.3% as the hotels business saw 170bps expansion to 30.7%, followed by FMCG-others (+150bps to 11%). Profitability in the paper and paperboard segment was dented by lower realisations and a spike in input costs. Adj. PAT grew 6% YoY to Rs 48.9bn with margin gains of 60bps.

**Operating environment remains challenging:** ITC mentioned that consumption demand has been relatively subdued, especially in the value segment and in rural markets due to subpar monsoons and a spike in food inflation during the quarter. However, management indicated that it is seeing green shoots of recovery as the prospects of improved agricultural output, onset of the festive season, higher rural wages, and government spending on infrastructure augur well for a recovery in rural markets.

**Maintain BUY:** We expect ITC's growth to pick up as the ongoing demand recovery deepens. The cigarettes business continues to deliver strong volume growth and market share gains in the absence of competition from illicit trade. Further, the FMCG-others and hotels segment have both registered a healthy performance across markets and portfolios. Given robust cigarette sales and earnings visibility in the FMCG and hotels businesses, we maintain BUY on ITC with an unchanged SOTP-based TP of Rs 523.

## Key changes

Target	Rating
◀▶	◀▶

Ticker/Price	ITC IN/Rs 438
Market cap	US\$ 66.3bn
Free float	71%
3M ADV	US\$ 61.1mn
52wk high/low	Rs 500/Rs 325
Promoter/FPI/DII	0%/43%/57%


Source: NSE | Price as of 20 Oct 2023

## Key financials

Y/E 31 Mar	FY23A	FY24E	FY25E
Total revenue (Rs mn)	709,369	741,223	882,161
EBITDA (Rs mn)	256,649	271,482	319,342
Adj. net profit (Rs mn)	194,039	207,846	237,968
Adj. EPS (Rs)	15.4	16.5	18.9
Consensus EPS (Rs)	15.4	15.8	17.8
Adj. ROAE (%)	27.9	28.5	31.0
Adj. P/E (x)	28.4	26.5	23.2
EV/EBITDA (x)	21.2	20.1	17.1
Adj. EPS growth (%)	22.4	7.0	14.5

Source: Company, Bloomberg, BOBCAPS Research

## Stock performance



Source: NSE




**Fig 1 – Financial performance**

(Rs mn)	Q2FY24	Q1FY24	Q2FY23	QoQ (%)	YoY (%)	Estimates	Variance (%)
Revenue	177,745	171,645	171,080	3.6	3.9	177,716	0.0
EBITDA	64,542	66,701	62,591	(3.2)	3.1	68,763	(6.1)
Adj. PAT	48,981	51,049	46,198	(4.1)	6.0	51,384	(4.7)
Gross Margin (%)	60.2	61.8	60.3	(160bps)	(10bps)	61.5	(130bps)
EBITDA Margin (%)	36.3	38.9	34.0	(260bps)	230bps	38.7	(240bps)
Adj. PAT Margin (%)	27.6	29.7	27.0	(210bps)	60bps	28.9	(130bps)


Source: Company, BOBCAPS Research

**Fig 2 – Cigarettes revenue & EBIT margin**




Source: Company, BOBCAPS Research

**Fig 3 – Hotels revenue & EBIT margin**




Source: Company, BOBCAPS Research

**Fig 4 – FMCG-Others revenue & EBIT margin**




Source: Company, BOBCAPS Research

**Fig 5 – Agri revenue & EBIT margin**




Source: Company, BOBCAPS Research

**Fig 6 – Consolidated revenue & growth forecast**



Source: Company, BOBCAPS Research

**Fig 7 – EBITDA and margin forecast**



Source: Company, BOBCAPS Research

## Result highlights

### Cigarettes: Strong performance on a high base

- ITC's cigarettes business posted gross revenue growth of 9.1% YoY (2Y CAGR of 15.7%) in Q2FY24 led by sustained volume clawback from illicit trade on the back of deterrent action by enforcement agencies, innovation, premiumisation, enhanced product availability and stability in taxes.
- Higher costs of leaf tobacco and certain other inputs, along with higher taxes, were largely mitigated by calibrated pricing, an improved mix and strategic cost management.
- The company recently launched seven new cigarette brands: Classic Alphatec, Classic Verve Balanced Taste, American Club Clove Magik, Players Rush, American Club Smash, Capstan Victory, and GF Glostar.

### FMCG-Others: Robust growth across the portfolio

- Revenue in the FMCG-others segment grew 8.3% YoY (2Y CAGR of 14.5%) in Q2 on a high base. Growth was backed by a strong YoY increase in sales of *atta* (wheat flour), spices, personal wash products and *agarbatti* (incense sticks). *Classmate* notebooks and pens continued to witness strong traction as well.
- Segment EBITDA margins expanded 150bps YoY to 11% in Q2, supported by multi-pronged interventions such as premiumisation, supply chain agility, judicious pricing actions, digital initiatives and strategic cost management.
- The FMCG-others businesses continued to do well in both urban and rural markets as it expanded its distribution footprint and ramped up last-mile execution.
- Traditional as well as emerging channels (modern trade, ecommerce, and quick commerce) witnessed high traction.
- Certain categories such as biscuits, snacks, noodles and popular soaps witnessed increasing competitive intensity, including from regional players, against the backdrop of commodity price deflation.
- *Aashirvaad Atta* posted robust growth in Q2 with the value-added range sustaining its strong growth momentum due to an increased thrust on the modern trade and e-commerce channels.
- ITC continues to enhance its product portfolio under *Aashirvaad* with the launch of several differentiated variants, such as gluten-free flour, ragi flour, multi-millet mix, *rava*, roasted suji rava, organic pulses, besan and vermicelli.
- *Yippee* noodles sustained its position as a strong No. 2 brand amidst increasing competition.
- *Sunrise* spices posted robust growth during Q2 and ITC launched the *Swaad Bihar Ka* range of spices customised to regional tastes during the quarter.
- In personal care, the *Fiama* range of personal wash products fared well and *Savlon Cool* soap continued to garner an encouraging consumer response. In homecare, *Nimyle* floor cleaning registered strong sales.

- ITC's *Classmate* brand of notebooks strengthened its leadership position and the company saw sustained traction in the premium portfolio, comprising *Paperkraft*, *Classmate Pulse* and *Classmate Interaktiv* continued to gain traction.

### **Hotels: Robust showing led by retail and MICE**

- ITC's hotels business continued its growth trajectory, with revenues increasing 21.2% YoY in Q2 (1.5x of Q2FY20) despite a high base. Segment EBIT swelled 50% YoY (7x of Q2FY20) led by the retail and MICE (meetings, incentives, conferences and exhibitions) segments.
- ITC witnessed strong growth in annual recurring revenue (ARR) across properties. Occupancy was flattish YoY mainly due to renovations and relatively fewer wedding dates during the quarter.
- The business continued with its strategy of offering a host of curated propositions across accommodations and iconic cuisine brands to augment revenues across properties.
- Segment EBITDA margin expanded 170bps YoY to 30.7% driven by higher RevPAR, curated packages, premium F&B offerings and strategic cost management initiatives.

### **Paper, paperboard & packaging: Still subdued**

- ITC's paper, paperboard & packaging segment posted a 9.5% YoY decline in Q2 revenue (2Y CAGR of +6.4%) owing to a sharp drop in realisations. Margins were further drained by high input costs, primarily of wood and coal.
- The Q2 performance was affected by low-priced Chinese supplies and muted demand in export markets, a sharp reduction in global pulp prices, relatively subdued domestic demand and a high base effect.
- Management believes realisations and global pulp prices are likely to have bottomed out and highlighted early signs of demand revival in value-added products and recycled boards towards the end of the quarter.

### **Agri business: Ban on wheat & rice exports continues to impact growth**

- Agri business revenue (excluding wheat & rice exports) grew 26.4% YoY on the back of sales of value-added agricultural products and leaf tobacco.
- During the quarter, stock limits on wheat, the ban on non-basmati rice exports and export duty on parboiled rice limited business opportunities.
- Capacity utilisation of the recently commissioned state-of-the-art value-added spice processing facility in Guntur has ramped up.

## Valuation methodology

We expect ITC's growth to pick up as the demand climate improves. The cigarettes business continues to deliver strong volume growth and market share gains in the absence of competition from illicit trade. In addition, the FMCG-others and hotels segments have registered a healthy performance across markets and portfolios during Q2FY24. We expect margins to improve on the strength of premiumisation, easing input costs, operating leverage, increasing market penetration and innovation.

ITC continues to invest in expanding its distribution footprint, digital channels and also capacity in the FMCG, paper and agriculture segments. We expect the hotels business to perform well, backed by growth in ARR, a strong wedding calendar, demand during the Cricket World Cup and a strong pipeline of management contracts.

We maintain our target multiples across businesses, leading to an unchanged SOTP-based TP of Rs 523. Barring FMCG, we have valued ITC's businesses based on FY25E EV/EBITDA as follows: (i) cigarettes at 17.2x, (ii) hotels at 18.9x, (iii) agriculture at 6.2x, and (iv) paper at 6.5x. We assign the FMCG-others segment an EV/Revenue multiple of 7.1x on FY25E revenue. Considering the strong volume growth in cigarettes and earnings visibility in the FMCG and hotels businesses, we maintain BUY.

**Fig 8 – SOTP valuation summary**

EV/EBITDA	FY25E EBITDA	Multiple (x)	EV
Cigarettes	2,39,444	17.2x	41,18,431
Hotels	12,023	18.9x	2,27,228
Agri	22,377	6.2x	1,37,737
Paper	28,603	6.5x	1,85,917
EV/Revenue	FY25E Revenue	Multiple (x)	EV
FMCG	2,50,029	7.1x	17756,206
Enterprise Value			64,45,519
Less: Net debt			(58,439)
Market Value (Rs mn)			65,03,959
No. of shares (mn)			12,439
<b>Target Price (Rs)</b>			<b>523</b>

Source: BOBCAPS Research

## Key risks

Key downside risks to our estimates are:

- delayed rural recovery,
- a further increase in duty on cigarettes, and
- input cost inflation.

## Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
Britannia Industries	BRIT IN	13.4	4,580	5,844	BUY
Dabur India	DABUR IN	11.3	525	669	BUY
Godrej Consumer Products	GCPL IN	12.3	988	1,159	BUY
Hindustan Unilever	HUVR IN	71.4	2,495	3,069	BUY
ITC	ITC IN	66.3	438	523	BUY
Marico	MRCO IN	8.5	542	646	BUY
Nestle India	NEST IN	28.5	24,280	28,260	BUY
Tata Consumer Products	TATACONS IN	10.2	899	994	BUY
Zydus Wellness	ZYWL IN	1.2	1,568	1,556	HOLD

Source: BOBCAPS Research, NSE | Price as of 20 Oct 2023

## Financials

### Income Statement

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23A	FY24E	FY25E
<b>Total revenue</b>	<b>492,728</b>	<b>606,681</b>	<b>709,369</b>	<b>741,223</b>	<b>882,161</b>
EBITDA	170,027	206,584	256,649	271,482	319,342
Depreciation	16,456	17,324	18,090	19,174	22,078
EBIT	153,571	189,260	238,559	252,308	297,264
Net interest inc./(exp.)	(446)	(394)	(432)	(435)	(523)
Other inc./(exp.)	26,326	18,364	19,805	25,822	20,628
Exceptional items	0	0	(729)	0	0
EBT	179,451	207,230	258,661	277,695	317,369
Income taxes	45,553	52,373	64,384	70,319	79,977
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	(69)	175	490	470	576
<b>Reported net profit</b>	<b>133,829</b>	<b>155,031</b>	<b>194,767</b>	<b>207,846</b>	<b>237,968</b>
Adjustments	0	0	(729)	0	0
<b>Adjusted net profit</b>	<b>133,829</b>	<b>155,031</b>	<b>194,039</b>	<b>207,846</b>	<b>237,968</b>

### Balance Sheet

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23A	FY24E	FY25E
Accounts payables	43,187	44,173	46,590	34,876	40,667
Other current liabilities	42,944	51,160	55,714	55,714	55,714
Provisions	3,815	3,006	3,598	3,598	3,598
Debt funds	95	56	388	388	388
Other liabilities	41,211	45,982	57,153	57,153	57,153
Equity capital	12,309	12,323	12,428	12,428	12,428
Reserves & surplus	594,633	615,895	682,960	716,686	755,214
Shareholders' fund	606,942	628,219	695,388	729,114	767,642
<b>Total liab. and equities</b>	<b>738,193</b>	<b>772,596</b>	<b>858,830</b>	<b>880,843</b>	<b>925,160</b>
Cash and cash eq.	2,904	2,714	4,634	33,473	14,084
Accounts receivables	25,017	24,619	29,562	30,889	36,763
Inventories	103,972	108,642	117,712	119,682	143,558
Other current assets	10,952	13,061	15,618	15,618	15,618
Investments	249,809	249,505	295,580	280,335	309,023
Net fixed assets	191,539	202,074	211,171	214,453	219,722
CWIP	40,045	31,985	29,847	29,847	29,847
Intangible assets	20,179	20,402	27,459	27,459	27,459
Deferred tax assets, net	585	635	520	520	520
Other assets	93,190	118,960	126,728	128,567	128,567
<b>Total assets</b>	<b>738,193</b>	<b>772,596</b>	<b>858,830</b>	<b>880,843</b>	<b>925,160</b>

### Cash Flows

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23A	FY24E	FY25E
<b>Cash flow from operations</b>	<b>125,270</b>	<b>157,755</b>	<b>188,776</b>	<b>212,008</b>	<b>236,088</b>
Capital expenditures	(18,366)	(21,416)	(27,430)	(23,719)	(27,347)
Change in investments	52,592	(18,536)	(94,376)	15,245	(28,688)
Other investing cash flows	22,604	17,567	64,482	0	0
<b>Cash flow from investing</b>	<b>56,829</b>	<b>(22,385)</b>	<b>(57,323)</b>	<b>(8,474)</b>	<b>(56,035)</b>
Equities issued/Others	2,907	2,918	24,774	0	0
Debt raised/repaid	(570)	(597)	(598)	0	0
Interest expenses	(412)	(396)	(414)	0	0
Dividends paid	(188,674)	(137,883)	(153,971)	(174,120)	(199,441)
Other financing cash flows	412	153	149	0	0
<b>Cash flow from financing</b>	<b>(186,338)</b>	<b>(135,805)</b>	<b>(130,060)</b>	<b>(174,120)</b>	<b>(199,441)</b>
<b>Chg in cash &amp; cash eq.</b>	<b>(4,239)</b>	<b>(435)</b>	<b>1,392</b>	<b>29,414</b>	<b>(19,389)</b>
<b>Closing cash &amp; cash eq.</b>	<b>2,904</b>	<b>2,714</b>	<b>4,633</b>	<b>33,473</b>	<b>14,084</b>

### Per Share

Y/E 31 Mar (Rs)	FY21A	FY22A	FY23A	FY24E	FY25E
Reported EPS	10.7	12.4	15.5	16.5	18.9
Adjusted EPS	10.9	12.6	15.4	16.5	18.9
Dividend per share	15.3	11.2	12.4	14.0	16.1
Book value per share	49.0	50.7	56.1	58.8	61.9

### Valuations Ratios

Y/E 31 Mar (x)	FY21A	FY22A	FY23A	FY24E	FY25E
EV/Sales	11.1	9.0	7.7	7.3	6.2
EV/EBITDA	32.0	26.4	21.2	20.1	17.1
Adjusted P/E	40.3	34.8	28.4	26.5	23.2
P/BV	9.0	8.7	7.8	7.5	7.1

### DuPont Analysis

Y/E 31 Mar (%)	FY21A	FY22A	FY23A	FY24E	FY25E
Tax burden (Net profit/PBT)	74.6	74.8	75.0	74.8	75.0
Interest burden (PBT/EBIT)	116.9	109.5	108.4	110.1	106.8
EBIT margin (EBIT/Revenue)	31.2	31.2	33.6	34.0	33.7
Asset turnover (Rev./Avg TA)	66.7	78.5	82.6	84.1	95.4
Leverage (Avg TA/Avg Equity)	1.2	1.2	1.2	1.2	1.2
<b>Adjusted ROAE</b>	<b>22.0</b>	<b>24.7</b>	<b>27.9</b>	<b>28.5</b>	<b>31.0</b>

### Ratio Analysis

Y/E 31 Mar	FY21A	FY22A	FY23A	FY24E	FY25E
<b>YoY growth (%)</b>					
Revenue	(0.3)	23.1	16.9	4.5	19.0
EBITDA	(11.7)	21.5	24.2	5.8	17.6
Adjusted EPS	(13.4)	15.8	22.4	7.0	14.5
<b>Profitability &amp; Return ratios (%)</b>					
EBITDA margin	34.5	34.1	36.2	36.6	36.2
EBIT margin	31.2	31.2	33.6	34.0	33.7
Adjusted profit margin	27.2	25.6	27.4	28.0	27.0
Adjusted ROAE	22.0	24.7	27.9	28.5	31.0
ROCE	25.3	30.1	34.3	34.6	38.7
<b>Working capital days (days)</b>					
Receivables	19	15	15	15	15
Inventory	189	150	148	148	148
Payables	78	61	59	59	59
<b>Ratios (x)</b>					
Gross asset turnover	1.9	2.1	2.2	2.2	2.4
Current ratio	3.3	2.8	2.9	3.3	3.5
Net interest coverage ratio	344.5	480.8	552.2	579.6	568.7
<b>Adjusted debt/equity</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>

Source: Company, BOBCAPS Research | Note: TA = Total Assets

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

## Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**  
 Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**  
 SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**  
 Brand Name: **BOBCAPS**  
 Trade Name: **www.barodaetrade.com**  
 CIN: **U65999MH1996GOI098009**

Logo: 

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.  
 Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%

**HOLD** – Expected return from -6% to +15%

**SELL** – Expected return <-6%

**Note:** Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

### Ratings and Target Price (3-year history): ITC (ITC IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.



The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS’s prior written consent.

#### **Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014**

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS’s associates may have financial interest in the subject company. BOBCAPS’s associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### **Other disclaimers**

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an “as is” basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS’s judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the “Losses”) which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### **Distribution into the United Kingdom (“UK”):**

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd (“MSL”) who is authorised and regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom (MSL and its affiliates are collectively referred to as “MAYBANK”). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK’s legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the “Order”), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as “relevant persons”).

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### **No distribution into the US:**

This report will not be distributed in the US and no US person may rely on this communication.

#### **Other jurisdictions:**

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.